脂肪肝
医学
疾病
糖尿病
脂肪性肝炎
纤维化
胰高血糖素样肽1受体
内科学
受体
生物信息学
内分泌学
兴奋剂
生物
作者
Riccardo Nevola,Raffaella Epifani,Simona Imbriani,Giovanni Tortorella,Concetta Aprea,Raffaele Galiero,Luca Rinaldi,Raffaele Marfella,Ferdinando Carlo Sasso
摘要
To date, non-alcoholic fatty liver disease (NAFLD) is the most frequent liver disease, affecting up to 70% of patients with diabetes. Currently, there are no specific drugs available for its treatment. Beyond their anti-hyperglycemic effect and the surprising role of cardio- and nephroprotection, GLP-1 receptor agonists (GLP-1 RAs) have shown a significant impact on body weight and clinical, biochemical and histological markers of fatty liver and fibrosis in patients with NAFLD. Therefore, GLP-1 RAs could be a weapon for the treatment of both diabetes mellitus and NAFLD. The aim of this review is to summarize the evidence currently available on the role of GLP-1 RAs in the treatment of NAFLD and to hypothesize potential future scenarios.
科研通智能强力驱动
Strongly Powered by AbleSci AI